NCT06713798View on ClinicalTrials.gov

Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2030

Conditions
Metastatic Cancer LungAdvanced Lung CancerCBNPC Cancer
Interventions
DRUG

Atezolizumab 1200 mg IV

atezolizumab (intravenous 1200mg Q3W)

DRUG

Tiragolumab 600 mg IV

Tiragolumab (intravenous 600mg Q3W)

Trial Locations (5)

21079

Centre GF Leclerc, Dijon

33076

Institut Bergonié, Bordeaux

64109

Centre Hospitalier Cote Basque, Bayonne

86021

CHU de Poitiers, Poitiers

94800

Gustave Roussy, Villejuif

All Listed Sponsors
collaborator

Roche Global Development

OTHER

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER